Torrent Pharma Q1 FY27 Revenue Rises 55% to ₹4,921 Cr, PAT at ₹566 Cr
Torrent Pharmaceuticals reported Q1 FY27 consolidated revenues of ₹4,921 crore, a 55% YoY increase. Net profit after tax was ₹566 crore. India business revenues grew 19% to ₹2,157 crore. US revenues were up 36% to ₹418 crore, and Brazil revenues increased by 27% to ₹277 crore. JB Business revenues grew 10% to ₹1,201 crore.
The significant YoY growth in revenue, EBITDA, and net profit, coupled with strong performance in major markets and product segments, indicates a substantial positive impact on the company's financial standing and market position.
The company reported strong year-on-year growth in revenue and operating EBITDA, along with positive performance in key markets like India and the US. The increase in net profit also contributes to a positive sentiment.
Torrent Pharmaceuticals Limited announced its financial results for the first quarter of FY27 on July 30, 2026. The company reported consolidated revenues of ₹4,921 crore, marking a significant 55% year-on-year increase. Operating EBITDA stood at ₹1,664 crore, up 61% YoY, with an EBITDA margin of 33.8%. The net profit after tax for the quarter was ₹566 crore, a 3% increase YoY.
The company's base business revenues reached ₹3,720 crore, showing a 17% increase, with Operating EBITDA growing by 20% to ₹1,240 crore.
In India, the company's revenues grew by 19% to ₹2,157 crore, outperforming the Indian Pharmaceutical Market (IPM) growth of 12%. Torrent now holds the 1st rank in the IPM cardiac market. The Gx Semaglutide recorded a 36% market share in Q1 FY27.
Brazil operations saw revenues of ₹277 crore, up 27% YoY (3% in constant currency). The company undertook a one-time channel inventory reduction in Brazil during the quarter.
US revenues increased by 36% to ₹418 crore (23% in constant currency), driven by new launches and one-time opportunities.
Germany revenues grew by 3% to ₹318 crore (down 9% in constant currency), impacted by supply disruptions and lower tender offtake.
The JB Business segment reported revenues of ₹1,201 crore, a 10% increase YoY, with Operating EBITDA at ₹424 crore, up 34% YoY. Exceptional items in the JB Business were ₹19 crore.
Ameera Shah will be completing her term as an Independent Director on August 1, 2026.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.